MDM2、IGF1、STAT1、RAC1在骨巨细胞瘤的表达特点及临床意义

目的 探讨MDM2、IGF1、STAT1和RAC1在骨巨细胞瘤(GCT)中的表达及其与GCT复发的关系.方法 应用SP免疫组织化学方法检测MDM2、IGF1、STAT1和RAC1在50例骨巨细胞瘤中的表达.结果 MDM2:未复发组11/37阳性表达,复发组9/13阳性表达.IGF1:未复发组13/37阳性表达,复发组9/13阳性表达.STAT1:未复发组10/37阳性表达,复发组8/13阳性表达.RAC1:未复发组10/37阳性表达,复发组9/13阳性表达.其阳性表达与GCT复发均有高度相关性.结论 MDM2、IGF1、STAT1和RAC1在GCT中的表达与其复发有关,是影响预后、骨巨细胞瘤复发的危险因素,可作为帮助判断骨巨细胞瘤预后的指标.

Expressions and clinical significance of MDM2, IGF1, STAT1, and RAC1 in giant cell tumor of bone

Objective To investigate the expressions of MDM2,IGF 1,STAT 1,and RAC1 in giant cell tumor of bone (GCT) and the relationship with the recurrence.Methods Immunohistochemistry was used to detect the expressions ofMDM2,IGF1,STAT1,and RAC1 in 50 cases of giant cell tumor of bone.Results The positive staining of MDM2 was observed in 11 of 37 GCT tissues without recurrence and 9 of 13 GCT tissues with recurrence.The positive staining of IGF 1 was observed in 13 of 37 GCT tissues without recurrence and 9 of 13 GCT tissues with recurrence.The positive staining of STAT1 was observed in 10 of 37 GCT tissues without recurrence and 8 of 13 GCT tissues with recurrence.The positive staining of RAC1 was observed in 10 of 37 GCT tissues without recurrence and 9 of 13 GCT tissues with recurrence.The positive expressions of MDM2,IGF1,STAT1,and RAC1 highly correlated with GCT recurrence.Conclusions The expressions of MDM2,IGF1,STAT1,and RAC1 in GCT correlates with the recurrence of GCT.These markers are risk factors for the prognosis of giant cell tumor of bone.They can be used as biomarkers for evaluating the prognosis of GCT.